Sequoia Sciences
Sequoia Sciences Sequoia Sciences
High-throughput Natural Products Chemistry

About Us Science & Technologies Research & Development Publications Contact

Sequoia Sciences is a pharmaceutical company discovering and developing new medicines for the treatment of bacterial infections and cancers. Our development programs consist of small molecules targeting bacterial infections and cancers, and also vaccines for the treatment and prevention of recurrent urinary tract infections. Our goal is to improve the quality of life for those individuals significantly affected by recurrent and chronic bacterial infections and cancers.

Sequoia is engaged in research and development programs and collaborations with laboratories, universities, clinical research sites, and private businesses.  We have applied our microscale structure determination expertise to elucidate structures of natural products,  biosynthetic intermediates, and unexpected synthetic products for academic and industrial collaborators.  Contact us to determine the structure of your challenging compound.

Presentations | See All

Sequoia Sciences has been invited to present at "Natural Products and Drug Discovery - Future Perspectives" symposia in Vienna, Austria.

Mark O'Neil-Johnson, VP of Analytical Chemistry, has been invited to give a keynote lecture at "Natural Products and Drug Discovery - Future Perspectives" symposia organized by The University of Innsbruck. The symposia is to be held in Vienna, Austria, November 13-14, 2014.

Sequoia Sciences has been invited to preside over the "8th Annual European Bioinnovation Leaders Summit 2015 London".

Mark O'Neil-Johnson, VP of Analytical Chemistry, has been invited preside over the two day "8th Annual European Bioinnovation Leaders Summit 2015 London" organized by GBX Summits. The conference is to be held in London, February 10-11, 2015.


Recent Publications | See All

July, 2014: La Clair, J., Loveridge, S., Tenney, K., O'Neil-Johnson, M., Chapman, E., Crews, P., "In Situ Natural Product Discovery via an Artificial Marine Sponge." PLOS One, 2014, 9 (7), doi:10.1371/journal.pone.0100474

July, 2014: Zerbe, P., Chiang, A., Dullat, H., O'Neil-Johnson, M., Starks, C., Hamberger, B., Bohlmann, J., "Diterpene Synthases of the Biosynthetic System of Medicinally Active Diterpenoids in Marrubium vulgare," The Plant Journal, 2014, Accepted - Identifying Biosynthetic Intermediates at the Microgram Scale

June, 2014: Starks, C.M.; Norman, V.L.; Williams, R.B.; Goering, M.G.; Rice, S.M.; O'Neil-Johnson, M.A.; Eldridge, G.R. "Antibacterial Activity of Taxodium ascendens Diterpenes Against Methicillin-resistant Staphylococcus aureus." Natural Product Communications, 2014, 9 (8), 1129-1130

June, 2014: Kilgore, M., Rolf, M., Starks, C.M., O'Neil-Johnson, M., Kutchan, T.M., "Cloning and Characterization of a Norbelladine 4'-O-Methyltransferase Involved in the Biosynthesis of the Alzheimer's Drug Galanthamine in Narcissus spp." PLOS One, 2014, Accepted - Identifying Biosynthetic Intermediates at the Microgram Scale